ATE398139T1 - Analyse und separation von pdgf-proteinen - Google Patents

Analyse und separation von pdgf-proteinen

Info

Publication number
ATE398139T1
ATE398139T1 AT97948629T AT97948629T ATE398139T1 AT E398139 T1 ATE398139 T1 AT E398139T1 AT 97948629 T AT97948629 T AT 97948629T AT 97948629 T AT97948629 T AT 97948629T AT E398139 T1 ATE398139 T1 AT E398139T1
Authority
AT
Austria
Prior art keywords
isoforms
proteins
pdgf
clipped
methods
Prior art date
Application number
AT97948629T
Other languages
English (en)
Inventor
Michael Kunitani
An Tran
Hug Parker
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE398139T1 publication Critical patent/ATE398139T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
AT97948629T 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen ATE398139T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13

Publications (1)

Publication Number Publication Date
ATE398139T1 true ATE398139T1 (de) 2008-07-15

Family

ID=21866458

Family Applications (3)

Application Number Title Priority Date Filing Date
AT97954073T ATE253120T1 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe
AT97948629T ATE398139T1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
AT03012465T ATE426030T1 (de) 1996-12-13 1997-12-12 Verfahren zur expression von pdgf oder igr proteinen in hefe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97954073T ATE253120T1 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03012465T ATE426030T1 (de) 1996-12-13 1997-12-12 Verfahren zur expression von pdgf oder igr proteinen in hefe

Country Status (9)

Country Link
US (10) US6017731A (de)
EP (4) EP0946736B1 (de)
JP (4) JP4341859B2 (de)
AT (3) ATE253120T1 (de)
AU (2) AU5465498A (de)
DE (3) DE69738768D1 (de)
ES (1) ES2306462T3 (de)
PT (1) PT948538E (de)
WO (2) WO1998025963A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
EP0946736B1 (de) * 1996-12-13 2003-10-29 Chiron Corporation Verfahren zur expression von heterologen proteinen in hefe
AU771539C (en) * 1998-10-06 2005-01-13 Dyadic International (Usa), Inc. Transformation system in the field of filamentous fungal hosts
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
BRPI0412279A (pt) 2003-07-02 2006-09-19 Diversa Corp glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
WO2005055944A2 (en) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
CN103755800B (zh) * 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8114841B2 (en) * 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
SG161209A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
CA2615057A1 (en) * 2005-07-12 2007-01-18 Codon Devices, Inc. Compositions and methods for biocatalytic engineering
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
JP2009520949A (ja) * 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
WO2007092622A2 (en) * 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2662755C (en) * 2006-09-08 2017-04-04 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
ES2457527T3 (es) 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2668189C (en) 2006-11-03 2016-01-26 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8551751B2 (en) * 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
JP5864106B2 (ja) 2008-02-07 2016-02-17 バイオミメティック セラピューティクス， エルエルシー 仮骨延長のための組成物および方法
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
CA2735885C (en) 2008-09-09 2018-08-28 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
MX2012009687A (es) 2010-02-22 2012-11-29 Biomimetic Therapeutics Inc Metodos y composiciones de factor de crecimiento derivado de plaquetas y métodos para el tratamiento de tendinopatías.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) * 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
CN107106492B (zh) * 2014-10-14 2022-07-05 塞缪尔·林奇 用于治疗伤口的组合物
TW202124419A (zh) 2014-10-24 2021-07-01 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
CN113015782A (zh) * 2018-11-19 2021-06-22 巴斯夫欧洲公司 用于酵母的前导序列

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0487116B1 (de) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
DE3751632T2 (de) * 1986-08-13 1996-06-13 Zymogenetics Inc Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
AU600069B2 (en) 1986-11-14 1990-08-02 Institute Of Molecular Biology, Inc. Wound healing and bone regeneration
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
WO1991015231A1 (en) 1990-04-10 1991-10-17 Institute Of Molecular Biology, Inc. Wound healing
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
WO1992001716A1 (en) * 1990-07-23 1992-02-06 Zymogenetics, Inc. Protease resistant pdgf and methods of use
CA2093664C (en) * 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
DE69333930T8 (de) * 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
CA2161225C (en) 1993-04-22 2003-07-01 Sinil Kim Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
EP0755454B1 (de) * 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0946736B1 (de) * 1996-12-13 2003-10-29 Chiron Corporation Verfahren zur expression von heterologen proteinen in hefe
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Also Published As

Publication number Publication date
US20020055169A1 (en) 2002-05-09
DE69738768D1 (de) 2008-07-24
JP2001506497A (ja) 2001-05-22
EP1365028B1 (de) 2009-03-18
US6312923B1 (en) 2001-11-06
ES2306462T3 (es) 2008-11-01
DE69725881T2 (de) 2004-09-09
EP0946736A1 (de) 1999-10-06
US6897043B2 (en) 2005-05-24
EP0946736B1 (de) 2003-10-29
US20030036511A1 (en) 2003-02-20
ATE253120T1 (de) 2003-11-15
EP0948538B1 (de) 2008-06-11
EP1365028A1 (de) 2003-11-26
JP2008031173A (ja) 2008-02-14
EP1935901A1 (de) 2008-06-25
DE69739319D1 (de) 2009-04-30
PT948538E (pt) 2008-08-05
US6448382B1 (en) 2002-09-10
US7166446B2 (en) 2007-01-23
US6083910A (en) 2000-07-04
ATE426030T1 (de) 2009-04-15
AU5794598A (en) 1998-07-03
WO1998025963A1 (en) 1998-06-18
DE69725881D1 (de) 2003-12-11
WO1998026080A1 (en) 1998-06-18
US20060252695A1 (en) 2006-11-09
US7084262B2 (en) 2006-08-01
JP2008119008A (ja) 2008-05-29
AU5465498A (en) 1998-07-03
US6706496B2 (en) 2004-03-16
EP0948538A1 (de) 1999-10-13
US6017731A (en) 2000-01-25
US20030077831A1 (en) 2003-04-24
JP4275741B2 (ja) 2009-06-10
US6083723A (en) 2000-07-04
JP4341859B2 (ja) 2009-10-14
US20050124042A1 (en) 2005-06-09
JP2001518073A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
DE69738768D1 (de) Analyse und separation von pdgf-proteinen
DE69513751D1 (de) Reinigung von Alpha-l-proteinaseinhibitor mittels neuen chromatographischen Trennungsbedingungen
RU95115239A (ru) Аналог эритропоэтина
DK0699687T3 (da) Fremgangsmåde til oprensning af rekombinant humant serumalbumin
IT1182721B (it) Procedimento di purificazione di proteine ossee
DK174484A (da) Fremgangsmaade til chromatografisk fraktionering af plasmaproteiner
MX9203128A (es) Eritropoietina homogenea.
ATE73856T1 (de) Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
NO863902D0 (no) Fremgangsmaate ved opprensing av proteiner.
DE69331507D1 (de) Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin
FR2562415B1 (fr) Bistouri electrique, pour chirurgie arthroscopique
FI871288A (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
DE69637734D1 (de) Menschliches alpha-endokin
BR9004626A (pt) Processo para preparar um concentrado estavel de complexo de fator viii-fator de von willebrand,concentrado de complexo de fator viii-fator de von willebrand e concentrados de proteina derivados de plasma
ES2070855T3 (es) Metodo para purificar una proteina.
FI862152A0 (fi) Anordning foer bestaemning av graden av konsistens hos en egenskap foer ett omraode i en diskreta bildelement uppdelad bild.
SG52497A1 (en) Separation procedure for LP(A) by means of electrophoresis gels for the implementation of this procedure & application to the in vitro (pls see file for full title)
BR9301641A (pt) Processo para produzir uma preparacao de fator viii,altamente purificada e uso
DK0789767T3 (da) Fremgangsmåde til fremstilling af oprensede papilomavirusproteiner
EE200200595A (et) Hemostaatiliselt aktiivne vWF sisaldav ravimpreparaat ja meetod selle valmistamiseks
Tijssen et al. An efficient two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis method for simultaneous peptide mapping of protein contained in a mixture
ES2193349T3 (es) Metodo para la produccion de rdspa alfa1.
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE69702890D1 (de) Methode zur Vorbereitung und Reinigung von 1,1,1.-Tris(4-hydroxyphenyl)ethan
DE3765163D1 (de) Steuerschaltung fuer eine lichtbogenlampe.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0948538

Country of ref document: EP